Daejung Chemicals & Metals Co., Ltd. Overview
Daejung Chemicals & Metals is a small-cap Korean specialty chemical manufacturer that has built a niche in laboratory reagents, high-purity and HPLC-grade solvents, electronic-grade solvents and pharmaceutical excipient-type active ingredients. The company sells to a fragmented base of research institutes, universities, hospitals, chemical producers and pharmaceutical manufacturers, and supplements its own catalogue of roughly 2,000 manufactured items with resale of some 20,000 imported global-brand products. Revenue reached a record KRW 108.1 bn in FY2025, with an operating margin of about 10%, and trailing-twelve-month operating income to June 2026 climbed to roughly KRW 15.9 bn. The balance sheet is conservatively funded, holding about KRW 75.7 bn of cash and short-term deposits against only KRW 6.9 bn of borrowings at end-FY2025. Family-controlled and trading near half of book value, the company is a cash-rich, low-growth compounder whose 50:50 joint venture with SK Chemicals gives it a foothold in semiconductor and OLED solvent supply chains.
What the company does
Daejung manufactures and distributes chemical reagents (substances used to detect, measure or react with other materials in laboratory, quality-control and industrial settings) and a smaller line of pharmaceutical raw materials. According to the business description in its DART filings, as summarized by ValueLine (26.2Q update), the company produces general, analytical, diagnostic and specialty test reagents, electronic-grade solvents and pharmaceutical raw materials for domestic and overseas customers. Its main products are various alcohols, acetonitrile, tetrahydrofuran (THF) and ethyl acetate.
The company's filings divide the business into two reporting areas:
-
Reagent business — chemicals used for detection and quantification reactions in R&D, bio-industry and environmental testing, plus higher-volume industrial and electronic-grade solvents.
-
Pharmaceutical raw materials (API) business — research, manufacture and supply of raw materials, principally excipient-type ingredients, to finished-drug manufacturers.
Morningstar's profile lists four business areas: Reagents, Raw materials for medicines, New materials, and Order-made (custom) synthesis. It cites acetaldehyde, acetamide, HPLC solvents and benzyl alcohol as example products. The Chemknock industrial directory lists further business areas: electronic materials, veterinary drug ingredients and food additives.
Business and revenue model
| Revenue stream (2Q26 revenue basis, Butler) | Share of revenue |
|---|---|
| Other manufactured products (aggregated) | 51% |
| Merchandise (resold third-party goods) | 38% |
| Tetrahydrofuran | 4% |
| Ethyl acetate | 4% |
| n-Hexane | 4% |
The revenue model is almost entirely product sales. There is no subscription, licensing or service revenue of any significance. Two product streams drive sales:
Manufactured products ("products"): reagents, solvents and API materials made at the Siheung site. Named large-volume lines include THF, ethyl acetate and n-hexane, each about 4% of 2Q26 revenue (Butler, product mix based on the 1H26 report).
Merchandise ("goods", 상품): resale of third-party reagents and laboratory chemicals. These were about 38% of 2Q26 revenue (Butler). The 2019 eBest brief described the company as stock-selling about 20,000 products from major global makers alongside about 2,000 of its own manufactured items.
Note: shares sum to about 101% because of rounding in the source.
Value-chain position
Daejung sits in the mid-stream of the fine-chemicals value chain. It buys commodity or technical-grade feedstocks such as solvents and inorganic salts, purifies, formulates and packages them to reagent, HPLC, electronic or pharmacopoeia grades, and sells them in small lots (laboratory) or larger lots (industrial and electronic solvents, API). Raw materials accounted for about KRW 41.4 bn of FY2025 cost of sales of KRW 85.5 bn, or roughly 48%. This makes feedstock pricing and purification yields the main gross-margin drivers. Labour inside cost of sales was about KRW 5.5 bn, and depreciation about KRW 3.1 bn (ValueLine cost breakdown, FY2025).
Customer types and end-markets
| Customer group | Examples named in filings/press | Demand driver |
|---|---|---|
| Chemical and materials companies | LG Chem, Hanmi Fine Chemical, Hyosung (DART business summary via ValueLine) | Process solvents, QC reagents, electronic-grade solvents |
| Pharmaceutical manufacturers | Chong Kun Dang, Boryung, Korea United Pharm (ValueLine); Celltrion, Kyongbo Pharm (Financial News, Aug 2021, citing DART) | API/excipient raw materials, HPLC solvents, QC reagents |
| Research institutes, universities, hospitals | Named as core demand base by eBest (2019) | Analytical and general reagents |
| Electronics (semiconductor/OLED) | Addressed mainly via the SK Chemicals Daejung JV (Dealsite, Aug 2020) | High-purity solvents |
Independent characterization
Daejung is best understood as a high-mix, low-volume domestic reagent house with a growing industrial-solvent tail. Its moat rests on catalogue breadth, regulatory and quality approvals, local logistics for hazardous materials, and long customer relationships, not on proprietary technology. R&D spending is modest at about 1.6% of revenue. Growth has historically tracked the Korean reagent market: eBest reported a 2009–2018 sales CAGR of 7.9% against 7.7% for the domestic reagent market. Profitability is mid-single-digit to low-double-digit at the operating line and is supplemented by meaningful interest income on a large cash pile. The step-up in 1H26 earnings suggests operating leverage is available when volumes rise. Gross margin sits around 21–23%, below the mid-20s levels of 2016–2018, which points to a mix shift toward lower-margin merchandise and bulk solvents.
Strategy
Stated strategy themes
The reviewed sources do not provide verbatim strategy text from the FY2025 annual report or an investor day. The company holds no regular earnings calls and has no sell-side coverage. The themes below are drawn from company disclosures and profiles:
Customer-centric, environment-first, open management: The company positioned 2016 as a fresh start around customer respect, environmental priority and open management (Chemknock corporate profile, paraphrased).
Electronic-materials localization: eBest (2019) identified acceleration of import substitution in electronic materials as a key momentum driver, together with expansion of domestic pharma R&D.
Partnership-led entry into high-purity solvents: The 2020 SK Chemicals JV was explicitly aimed at improving high-purity solvent technology for semiconductors and OLED and at developing the reagent business (Dealsite, 2020).
Initiatives in the last 24 months
| Date | Initiative | Detail | Targets |
|---|---|---|---|
| 26 Mar 2026 | Corporate Value-up Plan (voluntary disclosure) | Filed under the Korea Exchange value-up program. The disclosure states the company meets the high-dividend company criteria of the Restriction of Special Taxation Act: payout of 25% or more and dividend growth of 10% or more (FY2025 payout 25.1%, total dividend +13.1%). Dividends from such companies qualify for separate taxation at 14–30% for individual investors. | Detailed ROE, PBR or payout targets not available in reviewed sources |
| Feb 2026 | Dividend increase | FY2025 DPS raised 13.1% to KRW 475 | — |
| FY2025–1H26 | Capacity and working-capital build | Capex rose to KRW 3.8 bn (TTM Jun-2026) from KRW 1.5 bn (FY2025); construction in progress KRW 1.5 bn; inventory build | Project specifics not disclosed |
ESG and sustainability commitments: Not publicly disclosed.
Cost programs: Not publicly disclosed.
Medium-term financial targets and guidance
None publicly disclosed. The company does not issue earnings guidance.
Products & Services
Daejung does not publish prices, launch dates or version years for individual reagents. All pricing models are "not publicly disclosed." Catalogue items are sold per unit (bottle or drum) through direct sales and distributors. The catalogue below is compiled from Simply Wall St (S&P Global description), Morningstar, ValueLine (DART business summary), Chemknock and eBest.
Reagent segment — own-manufactured products
| Product line | Description and key specifications | Target customer | Named flagship items |
|---|---|---|---|
| General analytical reagents — organic | Laboratory-grade organic chemicals for synthesis, extraction and analysis | Universities, research institutes, corporate labs | Acetaldehyde, acetamide, benzyl alcohol (Morningstar) |
| General analytical reagents — inorganic | Inorganic salts, acids and bases at reagent grade | Labs, QC departments | Not individually named in reviewed sources |
| Indicators | Acid-base, redox and complexometric indicators | Analytical and teaching labs | Not individually named |
| High-purity reagents | Higher-assay grades with tighter impurity limits | Analytical labs, pharma QC | Not individually named |
| pH standard solutions | Calibrated buffer solutions for pH meter calibration | QC labs, environmental labs | pH standard solution (S&P Global description) |
| Normal (volumetric) solutions | Standardized titrants of defined normality | Titration-based QC | Normal solutions |
| Karl Fischer moisture reagents | Reagents for water-content determination | Pharma, petrochemical and food QC | KF moisture reagents |
| HPLC solvents | Low-UV-absorbance, low-residue solvents for liquid chromatography | Pharma and biotech analytical labs, CROs | Acetonitrile, methanol, THF (HPLC grade) |
| Toxic and heavy-metal test reagents | Reagents for mineral and heavy-metal toxicity analysis | Environmental and food-safety testing labs | Heavy-metal test reagents |
| Pesticide residue detection reagents | Residue-analysis grade solvents and reagents | Food-safety and agricultural testing | Pesticide-residue reagents |
| Electronic-grade reagents | Low-metal, low-particle grades for electronics processes | Electronics and display makers | Electronic-grade reagents (S&P Global description) |
| Diagnostic reagents | Reagents for clinical and diagnostic testing (eBest category) | Hospitals, diagnostic labs | Not individually named |
Reagent segment — bulk and industrial solvents
| Product | Use | Disclosed revenue weight |
|---|---|---|
| Tetrahydrofuran (THF) | Polymer, pharmaceutical and HPLC solvent | About 4% of 2Q26 revenue |
| Ethyl acetate | Extraction, coatings and pharmaceutical processing | About 4% of 2Q26 revenue |
| n-Hexane | Extraction and chromatography solvent | About 4% of 2Q26 revenue |
| Acetonitrile | HPLC and pharmaceutical synthesis solvent | Named main product (DART summary); weight not disclosed |
| Methyl alcohol (methanol) | HPLC and general solvent | Named product; weight not disclosed |
| Other alcohols | Various grades | Named main product group; weight not disclosed |
Reagent segment — merchandise (resale)
| Line | Description | Scale |
|---|---|---|
| Global-brand reagent distribution | Stock sales of products from major international reagent makers | About 20,000 SKUs (eBest, 2019); about 38% of 2Q26 revenue |
Pharmaceutical raw materials (API) segment
| Line | Description | Customers |
|---|---|---|
| Excipient-type APIs | Raw materials used as excipients or inputs in finished-dose drugs | Chong Kun Dang, Boryung, Korea United Pharm, Celltrion, Kyongbo Pharm (named in filings and press) |
| Specific APIs | Morningstar cites benzyl alcohol and acetamide as product examples. Company staff stated in 2020 that Daejung does not produce dexamethasone itself but imports it when needed (Dealsite, Aug 2020). | Pharma manufacturers |
Other business areas (per directory and Morningstar profiles)
| Area | Status |
|---|---|
| New materials / electronic materials | Listed as business area; JV with SK Chemicals targets semiconductor and OLED high-purity solvents |
| Order-made (custom) synthesis | Listed by Morningstar; scale not disclosed |
| Veterinary drug raw materials | Listed by Chemknock; scale not disclosed |
| Food additives | Listed by Chemknock; scale not disclosed |
Financial Narrative
All figures are separate K-IFRS, KRW bn unless stated. Source: DART annual reports FY2021–FY2025 as compiled by ETF Shopping and ValueLine; FY2025 detail and 1H26 trailing figures from ValueLine (DART 26.2Q update). Diluted EPS equals basic EPS; no dilutive instruments were identified.
Income statement
FY2025 income-statement detail (ValueLine, DART):
EBITDA note: ValueLine displays FY2025 EBITDA of KRW 17.6 bn. That figure does not reconcile with operating income plus reported depreciation and amortization (KRW 34.2 bn PP&E depreciation and 1.3 bn amortization in 억원 terms, i.e., KRW 3.4 bn and 0.1 bn).
Commentary:
Revenue: Revenue grew steadily from KRW 60.9 bn (FY2016) to KRW 96.6 bn (FY2022), then stalled for two years (FY2023 −3.4%, FY2024 −1.0%). That stall coincided with post-pandemic normalization of pharma and lab demand and weaker solvent prices. FY2025 broke out to a record KRW 108.1 bn (+17.1%), and momentum continued into 2026: TTM revenue to June 2026 reached KRW 119.3 bn.
Gross margin: Gross margin structurally compressed from about 25% (FY2016–FY2017) to about 20–23% (FY2021–FY2025). This is consistent with a rising share of merchandise and bulk solvents, and with feedstock inflation in 2021. FY2025 gross margin of 20.9% was flat on FY2024 despite higher volumes. TTM gross margin to June 2026 improved to about 22.7% (KRW 27.1 bn on KRW 119.3 bn).
Operating leverage: SG&A is largely fixed, rising only from about KRW 10.7 bn (TTM Jun-2025) to KRW 11.2 bn (TTM Jun-2026) while revenue grew about 23%. As a result, TTM operating income jumped to KRW 15.9 bn and the TTM operating margin to 13.3%.
Below-the-line earnings: Interest income on cash and deposits (KRW 2.8 bn in FY2025) and associate-related gains (KRW 1.5 bn) push net income above operating income. These items lifted net margin to 12.5% in FY2025.
Interim and trailing performance (1H26)
Q2 2025 is derived by the analyst from the change in ValueLine trailing-twelve-month series between March and June 2026, using the Q2 2026 reported figures (ETF Shopping). Treat as indicative.
Balance sheet
FY2021 balance sheet line items were not available in the sources reviewed. Four fiscal years are shown, with 1H26 in a separate table.
Net debt is calculated by the analyst as total debt minus cash and short-term financial instruments; small lease liabilities are excluded. ETF Shopping reports liabilities-to-equity of 21% for FY2021.
1H26 balance sheet (30 June 2026, KRW bn): total assets 220.5; cash 34.6; short-term financial instruments 48.9; inventories 18.6; trade receivables 18.6; PP&E 90.7 (construction in progress 1.5); short-term borrowings 6.9; total liabilities 31.8; equity 188.7; book value per share KRW 26,245; net cash about 76.6.
Commentary:
Liquidity: Liquid resources (cash plus short-term deposits) rose from KRW 46.4 bn (FY2022) to KRW 75.7 bn (FY2025) and KRW 83.5 bn (1H26). That is about 80% of the current market capitalization.
Leverage: Borrowings are minimal at KRW 6.9 bn, after a KRW 2.0 bn short-term loan repayment in 2025. No long-term debt or bonds are outstanding.
2023 balance-sheet step-up: In FY2023, land rose about KRW 9.3 bn and capital surplus about KRW 9.9 bn with an unchanged share count, while new machinery was commissioned. The accounting driver of the capital-surplus increase was not identified in reviewed sources and is flagged for verification against the FY2023 annual report notes.
Working capital in 1H26: Inventory jumped from KRW 14.3 bn to KRW 18.6 bn (+30%), with finished products at KRW 8.3 bn and raw materials at KRW 6.6 bn. This supports higher sales but warrants monitoring.
Cash flow
Full five-year cash-flow statements were not available in the sources reviewed. The available verified series are shown below.
Source: ETF Shopping (DART), ValueLine.
Commentary. Cash conversion was weaker in FY2025: operating cash flow of KRW 10.0 bn was 74% of net income, as receivables (−KRW 3.0 bn) and inventory (−KRW 2.6 bn) absorbed cash during the revenue surge. It recovered strongly in the TTM to June 2026, with operating cash flow of KRW 16.0 bn, or 94% of net income. Capex is light, at about 1.4% of revenue in FY2025 and about 3.2% in TTM 1H26. The FY2023 cash decline (−KRW 17.6 bn) mainly reflects the reallocation of cash into short-term deposits (+KRW 32.4 bn) plus the capacity investment; total liquidity actually rose.
Ratios
Analyst calculations from the DART data above. ROE and ROA use year-end balances. ROIC uses NOPAT at the effective tax rate over equity plus debt less cash and deposits.
Commentary. Return ratios are diluted by excess cash. Equity of KRW 183.6 bn carries about KRW 75.7 bn of liquid assets earning low single-digit interest. Excluding net cash, the operating business earns a materially higher return. The lengthening of the cash conversion cycle in FY2025, to 84 days from 68, came from lower payables days and slightly higher inventory days. It is a modest negative that partially reversed in 1H26 as payables rose to KRW 12.3 bn.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Representative products | Segment revenue FY2023–FY2025 |
|---|---|---|---|
Reagent | General, analytical, diagnostic and specialty reagents; high-purity, HPLC and electronic-grade solvents; resale of global-brand reagents | Alcohols, acetonitrile, THF, ethyl acetate, n-hexane, methanol; pH standards, volumetric solutions, Karl Fischer reagents, heavy-metal and pesticide-residue test reagents | Not publicly disclosed in reviewed sources |
Pharmaceutical raw materials (API) | Excipient-type raw materials and APIs for finished-drug makers | Benzyl alcohol, acetamide and related pharmacopoeia-grade materials (examples per Morningstar) | Not publicly disclosed in reviewed sources |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total revenue (KRW Bn) | 88.9 | 96.6 | 93.3 | 92.3 | 108.1 |
YoY growth (%) | 10.9 | 8.6 | -3.4 | -1.0 | 17.1 |
Group Entities
| Entity | Relationship | Stake | Latest total assets | Latest net income | Notes |
|---|---|---|---|---|---|
Daejung Chemicals & Metals Co., Ltd. | Listed parent / operating company | — | KRW 210.7 bn (FY2025) | KRW 13.5 bn (FY2025) | Reports on a separate basis |
SK Chemicals Daejung Co., Ltd. | Joint venture / associate (equity method) | 50% | KRW 17.5 bn | KRW 1.05 bn | Formed 2020 with SK Chemicals (50%); high-purity solvents and reagents |
Polus Co., Ltd. (㈜폴루스) | Minority investment | 0.3% | — | — | Unlisted; business not described in reviewed filings summary |
“—” = not publicly disclosed.
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 88.9 | 96.6 | 93.3 | 92.3 | 108.1 |
Cost of sales (KRW Bn) | 71.2 | 75.3 | 72.0 | 73.1 | 85.5 |
Gross profit (KRW Bn) | 17.7 | 21.3 | 21.3 | 19.2 | 22.6 |
Operating income (KRW Bn) | 7.9 | 11.6 | 11.0 | 8.5 | 11.2 |
Net income (KRW Bn) | 8.4 | 13.7 | 13.0 | 9.7 | 13.5 |
EPS basic and diluted (KRW) | 1,177 | 1,916 | 1,807 | 1,350 | 1,889 |
Dividend per share (KRW) | 300 | 400 | 450 | 420 | 475 |
Revenue growth (%) | 10.9 | 8.6 | -3.4 | -1.0 | 17.1 |
Gross margin (%) | 19.9 | 22.1 | 22.8 | 20.8 | 20.9 |
Operating margin (%) | 8.9 | 12.0 | 11.8 | 9.2 | 10.3 |
Net margin (%) | 9.5 | 14.2 | 13.9 | 10.5 | 12.5 |
Dividend payout ratio (%) | 25 | 21 | 25 | 31 | 25 |
Financial Analysis
| Line item (FY2025) | KRW Bn |
|---|---|
Revenue | 108.1 |
Cost of sales | 85.5 |
of which raw materials | 41.4 |
of which labour | 5.5 |
of which depreciation | 3.1 |
Gross profit | 22.6 |
SG&A | 11.4 |
of which salaries | 4.9 |
of which freight | 1.5 |
of which R&D expense | 1.8 |
of which commissions | 1.1 |
Operating income | 11.2 |
Net financial income | 3.6 |
of which interest income | 2.8 |
of which interest expense | 0.2 |
Associate-related gains (net) | 1.5 |
Other non-operating (net) | 0.3 |
Pre-tax income | 16.6 |
Income tax | 3.0 |
Effective tax rate (%) | 18.2 |
Net income | 13.5 |
EBITDA (operating income + D&A of c.3.5; analyst calculation) | 14.7 |
Income Statement and Margin Analysis (%)
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 60.9 | 66.5 | 73.8 | 79.6 | 80.2 |
Operating income (KRW Bn) | 8.4 | 9.0 | 9.2 | 10.4 | 10.1 |
Net income (KRW Bn) | 7.5 | 7.3 | 10.0 | 6.1 | 8.9 |
Gross margin (%) | 25.5 | 25.1 | 24.2 | 23.9 | 23.2 |
Operating margin (%) | 13.8 | 13.6 | 12.5 | 13.0 | 12.6 |
Dividend per share (KRW) | 250 | 270 | 300 | 300 | 300 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Analysis — Revenue CAGR FY2021–FY2025
| Measure | Value |
|---|---|
Revenue CAGR FY2021–FY2025 (4 years) | 5.0% |
Revenue CAGR FY2016–FY2025 (9 years) | 6.6% |
Operating income CAGR FY2021–FY2025 | 9.1% |
Net income CAGR FY2021–FY2025 | 12.6% |
DPS 5-year growth rate (ETF Shopping) | 9.6% p.a. |
Income Statement
| Metric (KRW Bn) | Q2 2025 (derived) | Q2 2026 | YoY change |
|---|---|---|---|
Revenue | 27.0 | 32.3 | +19.6% |
Operating income | 2.6 | 5.3 | +104% |
Net income | 2.3 | 4.8 | +111% |
Income Statement and Per-Share Data (TTM Jun-2025–TTM Jun-2026)
| Trailing-twelve-month metric (KRW Bn) | TTM Jun-2025 | TTM Dec-2025 | TTM Jun-2026 |
|---|---|---|---|
Revenue | 97.0 | 108.1 | 119.3 |
Gross profit | 19.6 | 22.6 | 27.1 |
Operating income | 8.9 | 11.2 | 15.9 |
Pre-tax income | 10.2 | 16.6 | 21.9 |
Net income | 9.0 | 13.5 | 17.0 |
EPS (KRW) | 1,254 | 1,884 | 2,370 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets (KRW Bn) | 173.8 | 196.3 | 202.2 | 210.7 |
Current assets (KRW Bn) | 74.4 | 89.5 | 88.3 | 108.6 |
Cash and cash equivalents (KRW Bn) | 28.4 | 10.8 | 20.9 | 31.0 |
Short-term financial instruments (KRW Bn) | 18.0 | 50.4 | 39.6 | 44.7 |
Trade receivables (KRW Bn) | 15.1 | 16.4 | 14.3 | 17.5 |
Inventories (KRW Bn) | 12.0 | 10.5 | 11.6 | 14.3 |
Property, plant and equipment (KRW Bn) | 83.6 | 94.4 | 91.6 | 89.7 |
of which land (KRW Bn) | 40.6 | 49.9 | 49.9 | 49.9 |
Intangible assets (KRW Bn) | 0.8 | 0.9 | 1.4 | 1.2 |
Goodwill (KRW Bn) | 0 | 0 | 0 | 0 |
Investment in associates (KRW Bn) | 8.1 | 7.9 | 5.8 | 7.0 |
Current liabilities (KRW Bn) | 23.1 | 22.7 | 22.2 | 20.6 |
Short-term borrowings (KRW Bn) | 8.9 | 8.9 | 8.9 | 6.9 |
Long-term borrowings (KRW Bn) | 0 | 0 | 0 | 0 |
Total debt (KRW Bn) | 8.9 | 8.9 | 8.9 | 6.9 |
Net debt (KRW Bn; negative means net cash) | -37.5 | -52.3 | -51.6 | -68.8 |
Total liabilities (KRW Bn) | 27.2 | 29.7 | 29.1 | 27.1 |
Total equity (KRW Bn) | 146.6 | 166.6 | 173.0 | 183.6 |
Retained earnings (KRW Bn) | 95.6 | 105.7 | 112.1 | 122.6 |
Working capital (KRW Bn) | 51.3 | 66.8 | 66.1 | 88.0 |
Book value per share (KRW) | 20,393 | 23,173 | 24,067 | 25,539 |
Liabilities-to-equity (%) | 18.6 | 17.8 | 16.8 | 14.7 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net change in cash and equivalents (KRW Bn) | 3.5 | -8.3 | -17.6 | 10.1 | 10.3 |
Dividends declared for the year (KRW Bn) | 2.2 | 2.9 | 3.2 | 3.0 | 3.4 |
Share buybacks (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Cash-flow item (KRW Bn)
| Cash-flow item (KRW Bn) | FY2025 | TTM Jun-2026 |
|---|---|---|
Operating cash flow | 10.0 | 16.0 |
of which working-capital change | -5.3 | -2.9 |
of which interest received | 2.6 | 2.7 |
of which income tax paid | -2.1 | -2.9 |
Capex (PP&E purchases) | 1.5 | 3.8 |
Free cash flow (OCF minus capex) | 8.5 | 12.2 |
Dividends paid | 3.0 | 3.4 |
Borrowings repaid | 2.0 | 2.0 |
Investing cash flow (incl. net deposit movements) | 5.4 | 2.1 |
Financing cash flow | -5.1 | -5.5 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE (%) | 9.3 | 7.8 | 5.6 | 7.4 |
ROA (%) | 7.9 | 6.6 | 4.8 | 6.4 |
Current ratio (x) | 3.22 | 3.94 | 3.98 | 5.27 |
Debt to equity (%) | 6.1 | 5.3 | 5.1 | 3.8 |
Asset turnover (x) | 0.56 | 0.48 | 0.46 | 0.51 |
Days sales outstanding | 57 | 64 | 57 | 59 |
Days inventory outstanding | 58 | 53 | 58 | 61 |
Days payables outstanding | 42 | 47 | 47 | 36 |
Cash conversion cycle (days) | 73 | 70 | 68 | 84 |
Single-period ratios (FY2025 unless stated) | Value | — | — | — |
ROIC (NOPAT KRW 9.2 bn / invested capital KRW 114.8 bn) | about 8.0% | — | — | — |
Net debt / EBITDA | Net cash (−4.7x) | — | — | — |
Interest coverage (operating income / interest expense) | about 47x | — | — | — |
ROE TTM Jun-2026 (ValueLine) | 9.0% | — | — | — |
Region (FY2025, Indicative) Overview
| Region (FY2025, indicative) | Share of revenue | Basis |
|---|---|---|
South Korea (domestic) | About 97–99% | Implied from ValueLine export series |
Exports (destinations not disclosed) | About 1–3% | ValueLine export series; destinations not disclosed |
Share Price and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Year-end share price (KRW) | 16,050 | 16,720 | 12,880 | 13,280 |
Year-end market cap (KRW Bn) | 115.4 | 120.2 | 92.6 | 95.5 |
Year-end P/E (x) | 8.4 | 9.3 | 9.5 | 7.0 |
Year-end P/B (x) | 0.79 | 0.72 | 0.54 | 0.52 |
Performance Details
| Performance (to 16–20 Oct 2026) | Return | Basis |
|---|---|---|
1 month | +0.3% | ETF Shopping |
6 months | +3.2% | ETF Shopping |
1 year | +14.6% | ETF Shopping (price only) |
About 3 years (vs. end-2023 close of KRW 16,720) | About −14% | Analyst calculation |
About 5 years (vs. 10 Aug 2021 intraday KRW 28,550) | About −49% | Analyst calculation; 2021 level reflected a speculative SK-theme spike |
52-week range | KRW 12,220–15,060 | ETF Shopping |
Valuation Multiples
| Multiple | Daejung (Oct 2026) | Soulbrain | Dongjin Semichem |
|---|---|---|---|
P/E (TTM) | 6.1x (ValueLine); 7.7x on FY2025 EPS (ETF Shopping) | 32.6x | 21.6x |
P/B | 0.55x | — | — |
EV/Sales (FY2025) | About 0.33x | — | — |
EV/EBITDA (FY2025) | About 2.4x | — | — |
EV/EBITDA (TTM Jun-26, EBITDA about KRW 19.5 bn) | About 1.4x | — | — |
Dividend yield | About 3.3% | 0.70% | 1.56% |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Dividend per share (KRW) | 250 | 270 | 300 | 300 | 300 | 300 | 400 | 450 | 420 | 475 |
Total dividend (KRW Bn) | 1.5 | 1.7 | 2.1 | 2.1 | 2.1 | 2.2 | 2.9 | 3.2 | 3.0 | 3.4 |
Payout ratio (%) | 20 | 23 | 21 | 35 | 24 | 25 | 21 | 25 | 31 | 25 |
Analyst Conclusions
Management guidance and consensus
Management provides no formal guidance, and no consensus estimates exist. A run-rate view based on disclosed data:
-
TTM revenue of KRW 119.3 bn and TTM operating income of KRW 15.9 bn to June 2026.
-
If 2H26 matches 2H25, FY2026 revenue would be about KRW 119 bn and operating income about KRW 16 bn.
-
If Q2 2026 momentum persists (Q2 revenue of KRW 32.3 bn annualizes to about KRW 129 bn), upside to these figures is plausible.
These are analyst extrapolations, not forecasts by the company.
Bull case
-
Earnings inflection with operating leverage. TTM operating margin expanded from about 9.2% (TTM Jun-2025) to 13.3% (TTM Jun-2026) on nearly flat SG&A. Sustained volume could lift operating income toward KRW 18–20 bn.
-
Asset-backed downside protection. Net cash of KRW 76.6 bn plus land at cost of KRW 49.9 bn plus the associate stake of KRW 6.4 bn total about KRW 133 bn, well above the KRW 105 bn market cap. Shares trade at 0.55x book and about 1.4x TTM EV/EBITDA.
-
Value-up and dividend catalysts. High-dividend company status and a 9.6% five-year DPS CAGR make a DPS increase to about KRW 550–600 plausible on TTM EPS of KRW 2,370 at a 25% payout. Samchun's stake may also attract attention to the discount.
Bear case
-
Structural margin erosion. Gross margin fell from 25.5% to about 21% over FY2016–FY2025, and merchandise is 38% of revenue. 1H26 gains may reflect cyclical solvent pricing rather than durable mix improvement.
-
Capital misallocation and governance discount. ROE has stayed below 10% for four years, cash keeps accumulating, buybacks are absent and family control is 51.37%. These suggest the valuation discount may persist regardless of earnings.
-
Working capital and cyclicality. The 30% inventory build in 1H26 and an 84-day cash conversion cycle create risk of write-downs or margin give-back if demand normalizes, as in FY2023–FY2024 when revenue fell two years running.
Key catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable |
|---|---|
| About 14 Nov 2026 (historical pattern) | Q3 2026 report: confirmation of the Q2 margin step-up and of inventory normalization |
| 31 Dec 2026 | Dividend record date |
| About late Feb 2027 | FY2026 DPS decision: test of value-up commitment |
| About mid-Mar 2027 | FY2026 annual report: segment detail, capex plans, JV results, purpose of the 1H26 construction-in-progress project |
| Ongoing | Samchun Pure Chemical stake: any change of purpose, increase or commercial tie-up |
| Ongoing | SK Chemicals Daejung growth in semiconductor and OLED solvents |
| Ongoing | Feedstock price trends for THF, ethyl acetate, acetonitrile and n-hexane; KRW exchange rate |
| Ongoing | Any buyback or cancellation to address the 0.55x P/B |
Concluding analyst verdict
Daejung Chemicals & Metals is a well-capitalized, consistently profitable but under-followed niche chemical supplier. After two flat years, it entered a clear earnings upswing in FY2025 and 1H26. FY2025 revenue reached a record KRW 108.1 bn. Trailing-twelve-month operating income to June 2026 of KRW 15.9 bn is roughly 40% above the FY2025 level. A largely fixed SG&A base is converting incremental volume into profit at high rates. The balance sheet is exceptionally conservative, with net cash of about KRW 77 bn at mid-2026 equivalent to roughly three-quarters of the market capitalization. Land is carried at historical cost, and the company has a 50% stake in a profitable joint venture with SK Chemicals.
The investment debate is therefore less about solvency or earnings quality than about capital allocation and the durability of margins. On the positive side, an enterprise value of only about KRW 28–36 bn against TTM EBITDA of about KRW 19.5 bn implies the market ascribes little value to the operating business. The new value-up framework and high-dividend tax status give management a reason to keep raising dividends. On the negative side, the gross-margin decline since FY2016, the heavy reliance on resale merchandise, low R&D intensity and single-digit ROE explain the persistent discount. Family control at 51.37%, minimal disclosure and zero analyst coverage limit any catalyst for re-rating.
The June 2026 entry of competitor Samchun Pure Chemical as a 5.74% holder adds an unpredictable strategic element. On balance, the evidence supports characterizing Daejung as a deep-value, asset-backed small cap with improving fundamentals. Upside depends on management converting earnings momentum into higher, more predictable shareholder returns: sustained payout increases, buybacks or productive deployment of surplus cash into higher-margin electronic-grade capacity. Investors should treat the Q3 2026 results and the FY2026 dividend decision as the decisive tests of whether the 1H26 inflection is durable and whether governance will narrow the valuation gap.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / education / age | FY2025 compensation |
|---|---|---|---|---|
Song Young-jun (송영준) | CEO and Representative Director | Not disclosed in reviewed sources | Not disclosed; related party of controlling shareholder; holds 14.36% | KRW 0.57 bn (only individual disclosed; disclosure threshold KRW 0.5 bn) |
Song Ki-seop (송기섭) | — | — | — | Below disclosure threshold or not disclosed |
Other directors and auditor | Not disclosed in reviewed sources | — | — | Average KRW 0.25 bn per director or auditor (5 persons) |
“—” = not publicly disclosed.
Major Shareholders
| Shareholder | Type | Stake | Date |
|---|---|---|---|
Song Ki-seop | Largest shareholder | 26.90% | End-FY2025 |
Song Young-jun | Related party (CEO) | 14.36% | End-FY2025 |
Song Young-jae | Related party | 10.11% | End-FY2025 |
Controlling group total | — | 51.37% | Unchanged Dec-2021 to Dec-2025 |
Samchun Pure Chemical Co., Ltd. | Corporate (competitor) | 5.74% | Short-form bulk-holding report filed 26 Jun 2026 |
National Pension Service | Institution | 1.00% | End-2024 (1.11% end-2023) |
Minority shareholders (10,963 holders) | Retail and other | 42.99% | End-FY2025 |
Treasury shares | Company | About 0.24% | 2026 |
Competitive Landscape
Key Competitors
| Competitor | Area of overlap | Ownership / listing | Relative positioning |
|---|---|---|---|
Samchun Pure Chemical (삼전순약공업) | Laboratory reagents, solvents, API raw materials | Private (Korea); founded 1969 | Closest domestic peer; markets about 6,000 own-produced items and about 25,000 imported items, with a large hazardous-materials logistics center and a third plant (Jincheon) completed in 2020 (company profile, 2022). Now a 5.74% Daejung holder. |
Duksan Pure Chemicals (덕산약품공업) | Laboratory reagents and solvents | Private (Korea) | — |
Merck KGaA (Sigma-Aldrich / Supelco) | Global analytical reagents, HPLC solvents | Listed (Germany) | Global leader in research chemicals; premium brand |
Thermo Fisher Scientific (Fisher Chemical, Acros, Alfa Aesar legacy) | Lab chemicals, solvents | Listed (US) | Global scale distributor and manufacturer |
Avantor (J.T. Baker, VWR) | Lab chemicals, high-purity solvents | Listed (US) | Global; strong in bioprocess and electronic grades |
Fujifilm Wako Pure Chemical | Reagents, electronic chemicals | Subsidiary of Fujifilm (Japan) | Strong Japanese reagent brand |
Kanto Chemical / Junsei Chemical | Reagents, electronic-grade chemicals | Private (Japan) | Japanese reagent houses active in Korea |
Honeywell (Burdick & Jackson) | HPLC and electronic solvents | Listed (US) | Specialist high-purity solvents |
Soulbrain | Electronic-grade chemicals for semiconductors | Listed (KOSDAQ: 357780) | Much larger electronic-chemicals player; cited by KoalaGains as competitor in semiconductor chemicals |
SK Specialty (formerly SK Materials) | Semiconductor specialty gases and chemicals | SK Group | Cited by KoalaGains as competitor in semiconductor chemicals |
Kukjeon Pharm (국전약품) | API raw materials; expanding into electronic materials | Listed (KOSDAQ) | Peer in API and electronic-material diversification; 1H26 revenue KRW 75.2 bn, operating income KRW 4.2 bn (Daily Pharm) |
Peer Comparison FY2025
| Metric | Daejung Chemicals & Metals | Kukjeon Pharm | Soulbrain | Dongjin Semichem |
|---|---|---|---|---|
Latest revenue | KRW 108.1 bn (FY2025) | KRW 75.2 bn (1H26 only) | — | — |
Revenue growth | +17.1% (FY2025) | +5% (1H26 YoY) | — | — |
Operating margin | 10.3% (FY2025); 13.3% (TTM Jun-26) | About 5.6% (1H26) | — | — |
R&D intensity | About 1.6% | — | — | — |
P/E | 6.1x (TTM) | — | 32.6x | 21.6x |
Dividend yield | About 3.3% | — | 0.70% | 1.56% |
Recent Developments
The company does not issue frequent press releases, and coverage is limited to regulatory filings and data-service updates. All verifiable items are listed.



